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Gene therapy has been considered to be a revolutionary development in medicine, whereby the cause 
and not the symptoms of the disease would be treated. These expectations have as yet not been 
realized, mainly due to lack of suitable vectors. Adenoviruses type 5 (Ad5) are the most commonly 
used vectors for gene therapy and have a great potential in this field.  
 
The main aim of this thesis was to generate genetically re-targeted and de-targeted Ad5 in order to 
create suitable vectors for gene therapy. To re-target the Ad5 vector ligands have been incorporated 
into the C-terminus at the pIX protein and at different positions in the fiber protein. Ligands that have 
been used are affibody molecules, with specificity for Taq DNA polymerase and for the tumour 
antigen HER2/neu, and a hyperstable single chain antibody, scFv, directed against β-galactosidase. In 
order to generate a virus with double specificity and determine which position is best suited for 
ligand–target cell interaction a re-targeted Ad5 vector with two different affibody molecules in the 
same genome was constructed. The re-targeted vectors were evaluated for growth, infectivity and 
specificity. For de-targeting assessments the neutralizing antibody reactivity in blood donor sera have 
been tested against a recombinant Ad5 vector with a shortened knobless fiber and a new cell binding 
ligand and a re-targeted vector with three different de-targeting steps have been evaluated for vector 
characterizations, tissue distribution and interaction with blood cells.  
 
Ligands that are to be used for re-targeting of Ad must be able to fold correctly and stably in the 
reducing milieu of the eukaryotic cytoplasm which is not conducive to the formation of disulphide 
bonds. Both the affibody molecules and the scFv did fulfill these criteria and could be rescued into 
functional Ad. Incorporation of ligands in the HI-loop of the fiber knob was shown to be superior to 
ligand insertions into truncated knobless fibers in terms of growth characteristics. It was possible to 
incorporate the scFv at the pIX protein with retained antigen binding when loaded on Ad5 virions, 
however transduction experiments could not be performed because a suitable cell line was not 
avalible. It was shown that generation of a vector with dual specificity was feasible, on the other hand 
it was important to evaluate which positions is best suited for efficient binding to target cell. The virus 
with a truncated knobless fiber and a new cellular ligand showed a much-reduced sensitivity to 
human pre-formed antibodies compared to wild type (WT) Ad5. The re- and de-targeted Ad vectors 
did not bind to normal tissues in mice as much as WT Ad5 and the association with human blood cells 
was much decreased for the recombinant vectors when compared to WT. 
 
In conclusion, both the affibody molecules and the scFv evaluated in this thesis can be used for genetic 
re-targeting of Ad5. Re-targeted viruses with ligands in the fiber often suffer from low growth rate, 
high infectivity indexes (PP/pfu) and low fiber content. However virus with ligand incorporation in 
the HI-loop does largely overcome those obstacles and the virus with ligand specificity for the tumour 
antigen HER2/neu may have relevance as a clinical vector. The adenovirus minor capsid protein IX 
can function as an anchor protein for relatively large ligand insertions, which is promising for future 
de-targeting purposes. Generation of recombinant viruses with double specificity may exploit the 
possibility to target several tumour antigens. The reduced neutralizing activity against the short 
knobless fiber and the reduced binding to normal tissues and interaction with blood cells of the re-
targeted viruses with additional de-targeting steps represents, to this author, an important step 
towards the construction of “stealth” adenoviruses for gene therapy.   
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